Is DBCA or DMAA more undervalued in 2026?

CirclFi compares D. Boral Acquisition I Corp. (DBCA) and Drugs Made In America Acquisiti (DMAA) using 13 institutional-grade valuation models. DBCA has a Quality of Company score of 3.7/10 while DMAA scores 5.0/10.

Which is a better buy — DBCA or DMAA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DBCA and DMAA valuations compare?

DBCA at $9.98 and DMAA at $10.61 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DBCA vs DMAA Valuation Comparison 2026 — Intrinsic Value Analysis

DBCA

Blank Checks

D. Boral Acquisition I Corp.

Quality

3.7

out of 10

Value Trap

—

Price

$9.98

Last close

Models

6/13

Active

DMAA

Blank Checks

Drugs Made In America Acquisiti

Quality

5.0

out of 10

Value Trap

—

Price

$10.61

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	DBCA Fair Value	DBCA Upside	DMAA Fair Value	DMAA Upside
Bayesian DCF	Intrinsic	$2.63	-73.7%	$0.87	-91.8%
Earnings Power Value	Intrinsic	—	—	$1.14	-89.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$9.32	-6.6%	$0.64	-93.9%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DBCA vs DMAA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DBCA vs DMAA — Which Stock Is More Undervalued?

DMAA scores higher with a 5.0/10 quality rating vs DBCA's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing D. Boral Acquisition I Corp. (DBCA) and Drugs Made In America Acquisiti (DMAA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DBCA currently trades at $9.98 with a QOC of 3.7/10, while DMAA trades at $10.61 with a QOC of 5.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).